Plain-English translation of NCT06045754 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication that works by targeting specific immune cells in the gut. You would receive combined with either or — two other medications that work differently to calm inflammation. The study wants to see if using two medications together works better than using them alone for people with Crohn's disease that hasn't responded well to previous treatments.
Many people with moderate to severe Crohn's disease don't get enough relief from single medications or stop responding to treatments over time. This trial is exploring whether combining two different types of medications that target inflammation in different ways might help patients whose disease has been hard to control.
You likely qualify if…
You likely don't qualify if…
You would participate for about 18 months total. In the first 6 months (Part A), you'd receive infusions of every 8 weeks along with regular doses of either (as injections) or (as an infusion or injection, depending on your weight). If the treatment is helping you by week 26, you'd move to Part B and receive alone for another 4 months. After that, you'd have a 20-week safety follow-up period where researchers check on how you're doing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States